4,217 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by Todd Asset Management LLC

Todd Asset Management LLC bought a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,217 shares of the specialty pharmaceutical company’s stock, valued at approximately $556,000.

Other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in Jazz Pharmaceuticals by 8.5% in the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock worth $246,092,000 after buying an additional 145,865 shares in the last quarter. State of New Jersey Common Pension Fund D grew its holdings in shares of Jazz Pharmaceuticals by 4.8% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 21,255 shares of the specialty pharmaceutical company’s stock valued at $2,801,000 after purchasing an additional 964 shares during the last quarter. Aberdeen Group plc bought a new stake in Jazz Pharmaceuticals in the third quarter worth $8,629,000. BTC Capital Management Inc. boosted its position in Jazz Pharmaceuticals by 2.5% during the third quarter. BTC Capital Management Inc. now owns 51,721 shares of the specialty pharmaceutical company’s stock valued at $6,817,000 after buying an additional 1,243 shares during the period. Finally, MidWestOne Financial Group Inc. grew its stake in shares of Jazz Pharmaceuticals by 13.1% during the third quarter. MidWestOne Financial Group Inc. now owns 39,271 shares of the specialty pharmaceutical company’s stock valued at $5,176,000 after buying an additional 4,559 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 77,500 shares of the business’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total transaction of $13,780,275.00. Following the sale, the director owned 393,332 shares of the company’s stock, valued at $69,938,362.92. The trade was a 16.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Patricia Carr sold 4,660 shares of the company’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00. Following the completion of the sale, the chief accounting officer owned 7,012 shares in the company, valued at approximately $1,200,454.40. This trade represents a 39.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 87,813 shares of company stock valued at $15,564,549 over the last 90 days. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ:JAZZ opened at $166.31 on Tuesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $182.99. The firm has a market capitalization of $10.10 billion, a P/E ratio of -27.40, a P/E/G ratio of 0.89 and a beta of 0.26. The stock has a 50 day moving average price of $167.54 and a 200-day moving average price of $147.79.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Piper Sandler reissued an “overweight” rating and issued a $219.00 target price (up previously from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Wall Street Zen upgraded Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. TD Cowen reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. JPMorgan Chase & Co. decreased their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research report on Monday, October 27th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $225.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, January 8th. Fourteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $205.67.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.